Showing results (51-60 of 100) with videos related to

Sort By:
Pageof 10
Archives of Internal Medicine|September 16, 2009
Improving outcomes in elderly patients with community-acquired pneumonia by adhering to national guidelines: Community-Acquired Pneumonia Organization International cohort study resultsForest W Arnold, A Scott LaJoie, Guy N Brock, et al.
American Journal of Infection Control|June 19, 2014
Evaluation of the effectiveness of improved hydrogen peroxide in the operating roomTimothy L Wiemken, Daniel R Curran, Robert R Kelley, et al.
Respiratory Medicine|June 30, 2018
Macrolide therapy is associated with lower mortality in community-acquired bacteraemic pneumoniaForest W Arnold, Gustavo Lopardo, Timothy L Wiemken, et al.
Lung|November 11, 2015
Macrolide Use and Neutrophil Function/Cytokine Levels in Hospitalized Patients with Community-Acquired Pneumonia: A Pilot StudyForest W Arnold, Jose Bordon, Rafael Fernandez-Botran, et al.
The Journal of the Kentucky Medical Association|October 19, 2007
Establishing a hospital program to improve antimicrobial use, control bacterial resistance and contain healthcare costs: the University of Louisville experienceForest W Arnold, Alpa Patel, Raul Nakamatsu, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|July 10, 2009
Clinical outcomes of HIV-infected patients hospitalized with bacterial community-acquired pneumoniaMaricar Malinis, John Myers, Jose Bordon, et al.
Contemporary Clinical Trials Communications|February 16, 2016
Real-Time Enrollment Dashboard For Multisite Clinical TrialsWilliam A Mattingly, Robert R Kelley, Timothy L Wiemken, et al.
Vaccines|April 27, 2026
Immunogenicity and Safety of Extended Dosing Intervals for Pfizer Pentavalent MenABCWY Meningococcal Vaccination in Healthy Adolescents: Results from a Randomized, Phase 2b StudyJake C Jones, Mary D Tipton, Lefteris Zolotas, et al.
Vaccine|July 28, 2021
A phase 3, randomized, double-blind study to evaluate the immunogenicity and safety of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive adults 18 through 49 years of ageNicola P Klein, Paula Peyrani, Kari Yacisin, et al.
Annals of the American Thoracic Society|February 2, 2017
Respiratory Health in Migrant Populations: A Crisis OverlookedFernando Holguin, M Anas Moughrabieh, Victoria Ojeda, et al.
Pageof 10